What the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.68%Below 5Y avg (2.17%)
Annual Rate
CNY 0.20Paid annual
Payout Ratio
103.3%High
Payback Period
58.0 yr
Last Ex-Dividend
May 29, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.97BCNY
1.03B · vs all stocks (USD)
Updated Aug 20, 2026
Trailing P/E
24.31x
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Revenue (TTM)
17.00BCNY
2.53B · vs all stocks (USD)
Updated Aug 20, 2026
Profit Margin
1.64%
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Beta
0.5780x
vs all stocks
Updated Aug 20, 2026
52-Week Change
-21.97%
vs all stocks
Updated Aug 20, 2026
Market Capitalization
6.97BCNY
1.03B · vs all stocks (USD)
Updated Aug 20, 2026
Enterprise Value
6.12BCNY
909.12M · vs all stocks (USD)
Updated Aug 20, 2026
Trailing P/E
24.31x
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Forward P/E
8.88x
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Price to Sales (TTM)
0.4019x
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Price to Book (MRQ)
0.8958x
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Enterprise to Revenue
0.3600x
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Enterprise to EBITDA
9.38x
vs Pharmaceutical Retailers peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 6.78×.Updated Aug 20, 2026
Gross Margin
33.09%
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Profit Margin
1.64%
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Operating Margin
6.34%
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Return on Assets (TTM)
2.10%
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Return on Equity (TTM)
3.73%
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Revenue (TTM)
17.00BCNY
2.53B · vs all stocks (USD)
Updated Aug 20, 2026
Revenue per Share (TTM)
29.62CNYUpdated Aug 20, 2026
Quarterly Revenue Growth
-7.00%
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Gross Profit (TTM)
5.46BCNY
810.35M · vs all stocks (USD)
Updated Aug 20, 2026
EBITDA (TTM)
903.20MCNY
134.14M · vs all stocks (USD)
Updated Aug 20, 2026
Net Income (TTM)
279.17MCNY
41.46M · vs all stocks (USD)
Updated Aug 20, 2026
Quarterly Earnings Growth (YoY)
9.80%
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Operating Cash Flow (TTM)
1.86BCNY
275.73M · vs all stocks (USD)
Updated Aug 20, 2026
Levered Free Cash Flow (TTM)
1.37BCNY
202.83M · vs all stocks (USD)
Updated Aug 20, 2026
Trailing Annual Dividend Rate
0.2000CNYUpdated Aug 20, 2026
Trailing Annual Dividend Yield
1.68%
vs all stocks
Updated Aug 20, 2026
5-Year Average Dividend Yield
2.17%
vs all stocks
Updated Aug 20, 2026
Payout Ratio
103.31%
vs Pharmaceutical Retailers peers
Provider-reported. Trailing Annual Dividend Rate ÷ Diluted EPS (TTM) on this page gives 41.67%.Updated Aug 20, 2026
Minority Interest (Equity)
153.84MCNYFY2025 · Dec 31, 2025
Revenue
17.34BCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
11.68BCNYFY2025 · Dec 31, 2025
Gross Profit
5.66BCNYFY2025 · Dec 31, 2025
Operating Income
745.35MCNY
110.70M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
406.59MCNYFY2025 · Dec 31, 2025
Income Tax Expense
134.89MCNYFY2025 · Dec 31, 2025
Net Income
271.71MCNYFY2025 · Dec 31, 2025
EBIT
539.82MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
1.99BCNYFY2025 · Dec 31, 2025
Research & Development
10.59MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
746.70MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
63.57MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
21.02MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
133.22MCNYFY2025 · Dec 31, 2025
EPS (Basic)
0.4571CNYFY2025 · Dec 31, 2025
EPS (Diluted)
0.4571CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
576.31MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
576.31MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
271.71MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
-8.27MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
812.00MCNYFY2025 · Dec 31, 2025
Free Cash Flow
534.06MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
1.52BCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
271.71MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
306.09MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-23.40MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
257.59MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-277.94MCNYFY2025 · Dec 31, 2025
Net Acquisitions
2.68MCNYFY2025 · Dec 31, 2025
Purchase of Investments
-2.91BCNYFY2025 · Dec 31, 2025
Sale of Investments
3.24BCNYFY2025 · Dec 31, 2025
Other Investing Activity
-80.48MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-25.54MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
745.20MCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-721.07MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-304.89MCNYFY2025 · Dec 31, 2025
Other Financing Charges
-1.26BCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
-1.54BCNYFY2025 · Dec 31, 2025
Shares Outstanding
585.60MSharesUpdated Aug 20, 2026
Float Shares
315.51MSharesUpdated Aug 20, 2026
% Held by Insiders
48.12%
vs all stocks
Updated Aug 20, 2026
% Held by Institutions
7.76%
vs all stocks
Updated Aug 20, 2026
Total Cash (MRQ)
3.30BCNY
489.61M · vs all stocks (USD)
Updated Aug 20, 2026
Total Cash per Share (MRQ)
5.74CNYUpdated Aug 20, 2026
Total Debt (MRQ)
2.53BCNY
375.36M · vs all stocks (USD)
Updated Aug 20, 2026
Total Debt to Equity (MRQ)
0.3310x
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Current Ratio (MRQ)
1.34x
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Book Value per Share (MRQ)
13.03CNYUpdated Aug 20, 2026
Total Assets
15.61BCNY
2.32B · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
8.95BCNYFY2025 · Dec 31, 2025
Total Liabilities
8.15BCNYFY2025 · Dec 31, 2025
Total Non-current Assets
6.66BCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
1.29BCNYFY2025 · Dec 31, 2025
Total Current Liabilities
6.86BCNYFY2025 · Dec 31, 2025
Cash
1.52BCNYFY2025 · Dec 31, 2025
Cash Equivalents
782.38MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
2.30BCNYFY2025 · Dec 31, 2025
Other Short-term Investments
759.84MCNYFY2025 · Dec 31, 2025
Accounts Receivable
1.36BCNYFY2025 · Dec 31, 2025
Inventory
3.67BCNYFY2025 · Dec 31, 2025
Accounts Payable
4.44BCNYFY2025 · Dec 31, 2025
Short-term Debt
1.37BCNYFY2025 · Dec 31, 2025
Other Current Liabilities
213.31MCNYFY2025 · Dec 31, 2025
Long-term Debt
1.27BCNYFY2025 · Dec 31, 2025
Common Stock (Book)
585.60MCNYFY2025 · Dec 31, 2025
Retained Earnings
4.50BCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
7.46BCNY
1.11B · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
150.00MCNYFY2025 · Dec 31, 2025
52-Week Low
9.41CNYUpdated Aug 20, 2026
52-Week High
15.41CNYUpdated Aug 20, 2026
52-Week Change
-21.97%
vs all stocks
Updated Aug 20, 2026
Beta
0.5780x
vs all stocks
Updated Aug 20, 2026
50-Day MA
11.04CNYUpdated Aug 20, 2026
200-Day MA
12.52CNYUpdated Aug 20, 2026
Avg 10-Day Volume
18.05MSharesUpdated Aug 20, 2026
Avg 30-Day Volume
12.98MSharesUpdated Aug 20, 2026
Diluted EPS (TTM)
0.4800CNYUpdated Aug 20, 2026
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
Where is this company structurally exposed?
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.